Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Sleep apnoea is a risk factor for severe COVID-19

Satu Strausz, Tuomo Kiiskinen, Martin Broberg, Sanni E. Ruotsalainen, Jukka Koskela, Adel Bachour, Finn Gen, Aarno Palotie, Tuula Palotie, Samuli Ripatti, Hanna M. Ollila
doi: https://doi.org/10.1101/2020.09.26.20202051
Satu Strausz
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
2Orthodontics, Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Finland
3Department of Oral and Maxillofacial Diseases, Helsinki University Hospital (HUH), Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tuomo Kiiskinen
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Broberg
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanni E. Ruotsalainen
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jukka Koskela
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
4Broad Institute of MIT and Harvard, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adel Bachour
6Sleep Unit, Heart and Lung Center, Helsinki University Hospital (HUH), Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Finn Gen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aarno Palotie
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
4Broad Institute of MIT and Harvard, Cambridge, MA, USA
5Analytic and Translational Genetics Unit (ATGU), Department of Medicine, Department of Neurology and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tuula Palotie
2Orthodontics, Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Finland
3Department of Oral and Maxillofacial Diseases, Helsinki University Hospital (HUH), Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuli Ripatti
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
4Broad Institute of MIT and Harvard, Cambridge, MA, USA
7Department of Public Health, University of Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanna M. Ollila
1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
4Broad Institute of MIT and Harvard, Cambridge, MA, USA
8Stanford University School of Medicine, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hanna.m.ollila@helsinki.fi
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To investigate if obstructive sleep apnoea (OSA) is an independent risk factor for severe COVID-19. To examine whether the risk for contracting COVID-19 is elevated among OSA patients.

Design and setting Registry based retrospective case-control study using Finnish nationwide health registries and the FinnGen Study cohort.

Participants Information regarding OSA diagnosis and COVID-19 infection was extracted from the FinnGen study (N=260,405) with a total of 305 patients who had a recorded PCR- validated COVID-19 infection including 26 (8.5%) individuals who were also OSA patients. Severe COVID-19 (N=83; 27.2%) was defined as an infection requiring hospitalization. Among the hospitalized individuals there were 16 (19.3%) with OSA diagnosis. In addition, we also included in our analysis previously reported risk factors for both severe COVID-19 or risk factors and comorbidities for OSA from FinnGen.

Main outcome measures OSA diagnosis, information concerning COVID-19 infection such as hospitalization, were derived from Finnish National Hospital Discharge Registry, Causes of Death Registry and the National Infectious Diseases Registry.

Results We show that OSA is a risk factor for COVID-19 hospitalization independent from age, sex, body mass index (BMI), hypertension, diabetes, coronary heart disease (CHD), asthma and chronic obstructive pulmonary disease (COPD), (p-unadjusted=1.04×10−4, OR- adjusted=5.14 [95%CI 1.31 to 22.91], p-adjusted=0.023). OSA was not associated with the risk of contracting COVID-19 (p=0.49).

Conclusion While an OSA patient’s risk of contracting COVID-19 is the same as non-OSA individuals, the OSA patients have a five-fold risk to be hospitalized when affected by COVID-19 than non-OSA individuals. Our findings suggest OSA as one of the risk factors for severe COVID-19. While these associations are statistically significant, they would benefit from replication in an independent cohort.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

SR was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312062), the Finnish Foundation for Cardiovascular Research, the Sigrid Juselius Foundation and University of Helsinki HiLIFE Fellow and Grand Challenge grants and Juho Vainio Foundation & Academy of Finland Covid-19 research funding. AP was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312074), and the Sigrid Juselius Foundation). HMO was supported by the Academy of Finland [Grant No 309643], Oskar Offlund foundation and Yrjo Jahnsson foundation and TP by the HUCH research grant. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Celgene Corporation, Celgene International II Sarl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc. Following biobanks are acknowledged for the project samples: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are members of BBMRI.fi infrastructure (www. bbmri.fi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Review Board of the Hospital District of Helsinki and Uusimaa approved the FinnGen study protocol (HUS/990/2017).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵*** Please see appendix for full list of contributors

Data Availability

The FinnGen data may be accessed through Finnish Biobanks FinnBB portal (www.finbb.fi) and THL Biobank data may be accessed through THL Biobank (https://thl.fi/en/web/thl-biobank).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 28, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Sleep apnoea is a risk factor for severe COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Sleep apnoea is a risk factor for severe COVID-19
Satu Strausz, Tuomo Kiiskinen, Martin Broberg, Sanni E. Ruotsalainen, Jukka Koskela, Adel Bachour, Finn Gen, Aarno Palotie, Tuula Palotie, Samuli Ripatti, Hanna M. Ollila
medRxiv 2020.09.26.20202051; doi: https://doi.org/10.1101/2020.09.26.20202051
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Sleep apnoea is a risk factor for severe COVID-19
Satu Strausz, Tuomo Kiiskinen, Martin Broberg, Sanni E. Ruotsalainen, Jukka Koskela, Adel Bachour, Finn Gen, Aarno Palotie, Tuula Palotie, Samuli Ripatti, Hanna M. Ollila
medRxiv 2020.09.26.20202051; doi: https://doi.org/10.1101/2020.09.26.20202051

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (47)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4855)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (628)
  • Health Policy (320)
  • Health Systems and Quality Improvement (203)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5339)
  • Intensive Care and Critical Care Medicine (330)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (780)
  • Public and Global Health (1816)
  • Radiology and Imaging (324)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)